NCT06657768View on ClinicalTrials.gov

A Study of LY4006895 in Healthy Participants With Early Symptomatic Alzheimer's Disease (AD)

PHASE1RecruitingINTERVENTIONAL
Enrollment

88

Participants

Timeline

Start Date

October 29, 2024

Primary Completion Date

July 31, 2027

Study Completion Date

July 31, 2027

Conditions
Alzheimer DiseaseHealthy
Interventions
DRUG

LY4006895

Administered IV

DRUG

Placebo

Administered IV

Trial Locations (7)

27710

NOT_YET_RECRUITING

Duke Early Phase Research Unit, Durham

30030

NOT_YET_RECRUITING

CenExel iResearch, LLC (CenExel iRA), Decatur

30331

NOT_YET_RECRUITING

Atlanta Center of Medical Research, Atlanta

32159

NOT_YET_RECRUITING

K2 Medical Research - The Villages, Lady Lake

32751

RECRUITING

K2 Medical Research, Maitland

90720

RECRUITING

Collaborative Neuroscience Network - CNS, Los Alamitos

08053

NOT_YET_RECRUITING

CenExel-HRI, Marlton

All Listed Sponsors
lead

Eli Lilly and Company

INDUSTRY